Work

AkurutEva/The-Global-Evolution-and-Clinical-Translation-of-Therapeutic-Neoantigen-NSCLC-Vaccines-: The Global Evolution and Clinical Translation of Therapeutic Neoantigen Non-Small Cell Lung Cancer Vaccines - A Scoping Review

Year: 2026
Type: software
Abstract: The Global Evolution and Clinical Translation of Therapeutic Neoantigen NSCLC Vaccines A scoping review of the historical evolution, global clinical-trial landscape, and translational readiness of therapeutic vaccines for non-small cell lung cancer (NSCLC). About this repository This repository accompanies the research manuscript "The Global Evolution and Clinical Translation of Therapeutic Neoantigen Non-Small Cell Lung Cancer Vaccines – A Scoping Review." It contains research materials supporting the identification, classification, descriptive analysis, and visualization of registered therapeutic NSCLC vaccine trials. Therapeutic NSCLC vaccine development has progressed from approaches targeting conventional tumor-associated antigens toward individualized neoantigen strategies enabled by tumor sequencing, computational antigen prioritization, and novel vaccine delivery platforms. This review maps that transition while evaluating clinical-development phases, geographic participation, vaccine platforms, therapeutic combinations, outcome measures, and cross-registry reporting consistency. Scope: This is a registry-based evidence synthesis, not an experimentally validated vaccine-design pipeline, a meta-analysis of treatment efficacy, or a source of clinical treatment recommendations. Study at a glance Metric Manuscript finding Registry search cutoff 17 August 2026 Records identified before screening/deduplication 323 Unique eligible therapeutic NSCLC vaccine trial protocols 184 Conventional tumor-associated antigen vaccine trials 145 (78.80%) Personalized neoantigen vaccine trials 39 (21.20%) Personalized neoantigen Phase III protocols identified 3 Neoantigen trials evaluating combination regimens 27/39 (69.23%) Neoantigen trials involving vaccine monotherapy ± adjuvant 12/39 (30.77%) Personalized trials found in both ClinicalTrials.gov and WHO ICTRP 16/39 (41.03%) Personalized trials found only through ClinicalTrials.gov 19/39 (48.72%) Personalized trials found only through WHO ICTRP search 4/39 (10.26%) The counts above describe the manuscript's defined trial-level dataset. A unique trial protocol is not the same as a registry record or a distinct vaccine product. Percentages use the denominators indicated. Research objectives Trace the historical development of therapeutic NSCLC vaccine trials, comparing conventional antigen approaches with personalized neoantigen strategies. Map the global geographic distribution and temporal registration trends of eligible trials. Characterize vaccine platforms, clinical phases, treatment combinations, recruitment status, and outcomes. Compare ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) for trial coverage and reporting discrepancies. Examine barriers to clinical translation, including efficacy evidence, manufacturing reproducibility, reporting completeness, and representation across regions. Methods The study followed the Joanna Briggs Institute (JBI) approach to scoping reviews and the PRISMA Extension for Scoping Reviews (PRISMA-ScR). Registered trials were identified through ClinicalTrials.gov and WHO ICTRP, with supplementary searches using vaccine product names and development codes. The historical registry search covered records from inception to 17 August 2026. Eligible records were interventional therapeutic vaccine trials involving NSCLC, including trials of mixed solid tumors that explicitly enrolled an NSCLC population. The personalized neoantigen subset was analyzed separately from the wider historical conventional-vaccine cohort. Observational, preclinical, prophylactic, non-NSCLC, and otherwise ineligible records were excluded as specified in the study protocol. Trial identifiers and study characteristics were reconciled to remove duplicate registry records while retaining distinct trial protocols. Extracted variables included registration dates, phase, recruitment status, enrollment, vaccine platform, location, sponsor, treatment regimen, and safety, immunogenicity, or clinical endpoints. Missing fields were coded as "Not reported." Descriptive analyses and visualizations were performed in R 4.5.2 using packages including tidyverse and ggplot2. No efficacy meta-analysis was performed. Interpretation of dates: The review maintains a registry inclusion cutoff of 17 August 2026. Where the revised manuscript discusses subsequent registry updates or milestones (for example, a September 2026 recruitment update), those updates should be interpreted separately from the original inclusion snapshot and are not evidence that the search cutoff was extended. Main findings Evolution of the therapeutic vaccine landscape The manuscript distinguishes three broad historical periods: 1991–1999: Early cellular and shared-antigen vaccine investigations. 2000–2015: Expansion of conventional tumor-associated antigen approaches. 2016–2026: Emergence and growth of sequencing-informed personalized neoantigen vaccine trials. Clinical development and vaccine platforms Among the 39 personalized neoantigen trial protocols, most were early-stage investigations. The review describes peptide/synthetic long-peptide, dendritic-cell, and mRNA/nucleic-acid approaches, including the emergence of late-stage individualized mRNA vaccine studies. Three Phase III trial protocols are highlighted for V940/mRNA-4157 (intismeran autogene): Trial Registry identifier Clinical-development focus INTerpath-002 NCT06077760 Adjuvant individualized neoantigen therapy in resected NSCLC INTerpath-009 NCT06623422 Resectable NSCLC without pathological complete response following neoadjuvant treatment INTerpath-014 NCT07513376 Completely resected high-risk Stage I NSCLC Important: Trial phase, registration, and planned enrollment do not establish clinical efficacy or regulatory approval. Trial status is time-sensitive and should be checked against the live registry before reuse. Combination therapies 27 of 39 (69.23%) personalized neoantigen trial protocols evaluated combinations involving immunotherapy or other anticancer modalities. These included checkpoint inhibitors, radiotherapy, chemotherapy, and targeted therapies. The remaining 12 (30.77%) examined vaccine monotherapy, with or without adjuvants. Registry coverage and data quality The 39 unique personalized neoantigen trial protocols were distributed across the two searches as follows: 19 found only in ClinicalTrials.gov; 16 found in both ClinicalTrials.gov and WHO ICTRP; 4 found only via WHO ICTRP. The manuscript documents differences in recruitment-status synchronization, phase terminology, enrollment targets, and endpoint detail. The trial FRAME-001 (NCT04998474 / EUCTR2021-003166-12-NL) illustrates why cross-registry linkage is needed to avoid double-counting. Translation and equity The review identifies outstanding challenges in demonstrating durable clinical benefit, standardizing personalized vaccine production, harmonizing registry reporting, and broadening geographic representation. The presence of neoantigen-specific immune responses alone should not be interpreted as proof of improved patient outcomes. Repository structure . ├── Datasets/ # Trial-level datasets and supporting extracts ├── Figures/ # Manuscript figures and visual summaries ├── Scripts/ # Data analysis and figure-generation scripts ├── NSCLC_Neoantigen_Codebook_Manual.pdf ├── The Global Landscape and Clinical Translation of │ Personalized Neoantigen Vaccines in NSCLC_Protocol v1.0.pdf └── README.md Directory contents may evolve. The protocol specifies the review methods; the codebook explains extracted fields and coding conventions. Consult those documents before attempting secondary analysis. Reproducing or exploring the analysis Clone the repository: git clone https://github.com/AkurutEva/The-Global-Evolution-and-Clinical-Translation-of-Therapeutic-Neoantigen-NSCLC-Vaccines-.git cd The-Global-Evolution-and-Clinical-Translation-of-Therapeutic-Neoantigen-NSCLC-Vaccines- Then review the protocol, inspect the codebook and available files in Datasets/, and examine the scripts in Scripts/ before running them. The manuscript reports R 4.5.2, tidyverse, and ggplot2; exact script-specific dependencies, input paths, and execution order should be taken from the scripts themselves. No unverified one-command reproduction procedure is claimed here. When reproducing counts, keep distinct the 184-trial overall cohort, the 39-trial personalized subset, registry records versus unique protocols, and trial-level versus vaccine-product-level analyses. Trial statuses may differ depending on registry export or update date. Data sources and reporting guidelines ClinicalTrials.gov WHO International Clinical Trials Registry Platform PRISMA-ScR reporting guidance Joanna Briggs Institute Please consult original trial records and applicable registry terms when redistributing or reusing third-party data. Citation and Zenodo archival DOI Zenodo DOI: forthcoming. A permanent DOI and version-specific archival citation will be added after the repository is deposited or connected to Zenodo. Please do not treat this placeholder as an issued DOI. Until then, cite the GitHub repository with its URL and an access date or specific commit/release: Akurut, E., et al. The Global Evolution and Clinical Translation of Therapeutic Neoantigen Non-Small Cell Lung Cancer Vaccines – A Scoping Review. Research repository. GitHub: https://github.com/AkurutEva/The-Global-Evolution-and-Clinical-Translation-of-Therapeutic-Neoantigen-NSCLC-Vaccines- The manuscript should be cited separately once a journal citation or preprint identifier is available. Corrections and contributions Corrections to trial identifiers, registry linkage, classifications, extraction fields, or analyses are welcome via GitHub Issues. Please provide the original registry identifier, supporting source, and date checked. License and reuse Consu
Author: EVA Akurut
Language: English
Subfield: Immunology
Open Access status: green
OpenAlex ID: W7225791570
Cites:
Cited by:
Related to: 10